Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.

Makito Miyake,Takuto Shimizu,Yuki Oda,Akira Tachibana,Chihiro Ohmori,Yoshitaka Itami,Keisuke Kiba,Atsushi Tomioka, Hiroaki Yamamoto,Kenta Ohnishi,Nobutaka Nishimura,Shunta Hori,Yosuke Morizawa,Daisuke Gotoh,Yasushi Nakai,Kazumasa Torimoto,Tomomi Fujii,Nobumichi Tanaka,Kiyohide Fujimoto

Japanese journal of clinical oncology（2023）

引用 5|浏览12

暂无评分

摘要

Objective response to 1 L chemotherapy and early induction of maintenance avelumab therapy may be associated with increased benefit from maintenance avelumab therapy.

查看译文

关键词

(MeSH term): urinary bladder neoplasms,avelumab,immunotherapy,kidney pelvis,ureter

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要